Free Trial
NASDAQ:NMRA

Neumora Therapeutics Q2 2025 Earnings Report

Neumora Therapeutics logo
$1.56 -0.40 (-20.41%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.64 +0.09 (+5.45%)
As of 08/1/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neumora Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.38
Beat/Miss
N/A
One Year Ago EPS
N/A

Neumora Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neumora Therapeutics Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Neumora Therapeutics Earnings Headlines

This Crypto Is Set to Explode in January
This Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.
See More Neumora Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neumora Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neumora Therapeutics and other key companies, straight to your email.

About Neumora Therapeutics

Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

View Neumora Therapeutics Profile

More Earnings Resources from MarketBeat